Welcome to: Rimonabant Information Source (kaufen rimonabant)

1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 |
Effective weight loss with Rimonabant
- generic accomplia rimonabant order
- rimonabant and caffiene
- kaufen rimonabant
- rimonabant hydrochloride
- rimonabant a stimulant
- buying rimonabant
- rimonabant and fda
Rimonabant Pricelist
Please wait while we load the price list
Rimonabant is the first selective CB1 receptor blocker to be approved for use anywhere in the world. In Europe, it is indicated for use in conjunction with diet and exercise for patients with a body mass index greater than 30 kg/m2, or patients with a BMI greater than 27 kg/m2 with associated risk factors, such as type 2 diabetes or dyslipidaemia. In the UK, it has been available since the end of July 2006. As of 2008, the drug was available in 56 countries. Rimonabant Acomplia works by blocking receptors of a substance called cannabinoid 1, which stimulates hunger and other cravings in the brain and is also present in fat tissue.
2 mm Hg. Related Results Lancet, BMJ studies sound concern over anti-obesity drug rimonabantRimonabant improves cardiovascular risk profileRimonabant improves cardiovascular risk profileNew drug application for rimonabant pulledRimonabant enhanced weight loss success, improved lipids This compares favorably with the mean reductions of 4. 7 mm Hg and 3. 0 mm Hg, respectively, in patients who received placebo, Dr. Luc Van Gall reported at the annual meeting of the European Society of Hypertension. This is the first indication that the cannabinoid receptor blocker may have a role in blood pressure reduction, and it is clearly good news for the treatment of obese or overweight patients who have multiple cardiovascular risk factors. But the drug should not be misconstrued as being an antihypertensive agent per se.
